Headlines about Catalent (NYSE:CTLT) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalent earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.8107996936075 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s scoring:
- Catalent (CTLT) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- Catalent (CTLT) Scheduled to Post Earnings on Wednesday (americanbankingnews.com)
- Zacks: Brokerages Anticipate Catalent (CTLT) Will Post Quarterly Sales of $610.64 Million (americanbankingnews.com)
- Catalent To Invest $5 Million at Somerset Site to Create New Drug Development and Modified Release Center of Excellence (prweb.com)
- Analysts Expect Catalent (CTLT) Will Post Earnings of $0.39 Per Share (americanbankingnews.com)
Shares of NYSE CTLT opened at $41.40 on Thursday. The company has a market capitalization of $5,623.38, a P/E ratio of 30.67, a price-to-earnings-growth ratio of 2.30 and a beta of 1.53. Catalent has a 1 year low of $28.76 and a 1 year high of $47.87. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78.
A number of research firms have recently commented on CTLT. Goldman Sachs began coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 target price for the company. Royal Bank of Canada set a $48.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Monday, February 5th. Stephens cut shares of Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a report on Wednesday, January 17th. Finally, Bank of America increased their target price on shares of Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Tuesday, February 6th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $45.75.
In other Catalent news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the transaction, the senior vice president now owns 46,986 shares in the company, valued at approximately $1,964,014.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.70% of the stock is owned by company insiders.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.